

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	10/730,172
Filing Date	12/06/03
First Named Inventor	Charles L. CYWIN et al
Art Unit	1614
Examiner Name	N/A
Attorney Docket Number	9/244-1-C1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
SJA		US- 6,232,320 B1	05/15/2001	Andrew O. Stewart, et al	
		US- 6,313,301 B1	11/06/2001	Shokyo Miki, et al	
		US- 6,579,882 B2	06/17/2003	Andrew O. Stewart, et al	
		US- 2001/0020030 A1	09/06/2001	Andrew O. Stewart, et al	
SJA		US- 5,656,638	08/12/1997	Federico C.A. Gaeta, et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
SJA		WO 03/037886 A2	05/08/2003	PHARMACIA CORPORATION		
		WO 01/68648 A1	09/20/2001	Aventis Pharma Deutschland GMBH		
		WO 01/58890 A1	08/16/2001	ASTRAZENECA AB		
		WO 01/30774 A1	05/03/2001	Aventis Pharma Deutschland GMBH		
SJA		WO 00/75145 A1	12/14/2000	ABBOTT LABORATOIRES		

Examiner
Signature

S. Huang


Date
Considered

11/12/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449, 07/97

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/730,172
Filing Date	12/06/03
First Named Inventor	Charles L. Cywin, et al.
Art Unit	1614
Examiner Name	N/A
Attorney Docket Number	9/244-1-C1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
SH		WO 00/61586	10/19/2000	GERRITSMA, Gerritina, et al.		
		WO 01/00610 A1	01/04/2004	Aventis Pharma Deutschland GMBH		
SH		WO 92/03427	03/05/1992	YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.		

Examiner Signature	<i>Se Huang</i>	Date Considered	11/12/04
--------------------	-----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project (06-03), no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/P

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	10/730,172
Filing Date	12/06/03
First Named Inventor	Charles L. CYWIN et al
Art Unit	1614
Examiner Name	N/A
Attorney Docket Number	9/244-1-C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SH		ALBERT S. BALDWIN, JR., The NF-kB and IκB Proteins: New Discoveries and Insights, Annu. Rev. Immunol. 1996, 14: 649-681	
		TOSHIKI MURATA, et al, Discovery of Novel and Selective IKK-B Serine-Threonine Protein Kinase Inhibitors. Part 1, Bioorganic & Medicinal Chem Letters, 2003 13:913-918 Elsevier Science Ltd.	
		XP-002254095 Abstract, "Synthesis of Novel Heterocyclic Compounds for Antitumor and Radioprotective Activities"	
		✓ M.-M. GHORAB, et al., "Synthesis of Novel Heterocyclic Compounds for Antitumor and Radioprotective Activities", Phosphorus, Sulfur, and Silicon, 1998 Vol. 134/135, pp 447-462	
		XP-002254099 Abstract, "Use of benzo- and pyrido-furan or -thiophene cpds. - as hypercalcaemia agents for treating osteoporosis"	
		XP-002254097 Abstract, "Synthesis and Antimicrobial Evaluation of Several New Pyridine, Thienopyridine and Pyridothienopyrazole Derivatives"	
		✓ F.A. ATTABY, et al., "Synthesis and Antimicrobial Evaluation of Several New Pyridine, Thienopyridine and Pyridothienopyrazole Derivatives", Phosphorus, Sulfur, and Silicone, 1999, Vol. 149, pp 49-64	
		E.I. KAIGORODOVA, et al., "Synthesis of Substituted 2-Alkyl(Aryl)Thio-3-Cyanopyridines and 3-Aminothieno[2,3-b] Pyridines", Chem. Heterocyclic Compounds, Vol. 32, No. 10, pp 1234-1238 1996	
SH		✓ G. WAGNER, et al., "Synthese neuer prim., sek. und tert. 3-Amino-thieno[2,3-b]pyridin-2-carbonsaureamide auf verschiedenen Wegen", Vol. 45, 1990, pp 102-109.	

Examiner
Signature*Sh Huang*Date
Considered*11/12/04*

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.